extract: 2025-12-01-who-glp1-global-guidelines-obesity

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
 
 The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO issued conditional recommendations (not full endorsements) for GLP-1s, acknowledging 'limited long-term evidence' and requiring countries to consider 'local cost-effectiveness, budget impact, and ethical implications.' The conditional framing and emphasis on budget impact analysis suggests WHO recognizes the chronic use cost challenge, particularly for low/middle-income countries where affordability is a barrier to sustained treatment.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the
 
 The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO's three-pillar framework for GLP-1 treatment explicitly positions medication as one component within a comprehensive approach including healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical interventions alone cannot address health outcomes driven by behavioral and social factors.
+
 ---
 
 Relevant Notes:

domains/internet-finance/futarchy-governed-memecoin-launchpads-face-reputational-risk-tradeoff-between-adoption-and-credibility.md

@@ -27,6 +27,12 @@ From the MetaDAO proposal:
 
 This claim extends futarchy-governed-permissionless-launches-require-brand-separation-to-manage-reputational-liability-because-failed-projects-on-a-curated-platform-damage-the-platforms-credibility by showing the reputational concern operates at the mechanism level, not just the platform level. The market's rejection of Futardio suggests futarchy stakeholders prioritize mechanism credibility over short-term adoption metrics.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
+
+Phonon Studio AI raised $88,888 target but ended in 'Refunding' status within one day (launched 2026-03-05, closed 2026-03-06). The project had live product traction (1000+ songs generated in first week, functional tokenized AI artist logic) but still failed to attract capital, suggesting futarchy-governed launches face quality perception issues even when projects demonstrate real product-market validation.
+
 ---
 
 Relevant Notes:

domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md

@@ -56,10 +56,16 @@ Hurupay raised $2,003,593 against a $3,000,000 target (67% of goal) and entered
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-03-futardio-launch-cloak]] | Added: 2026-03-16*
+*Source: 2026-03-03-futardio-launch-cloak | Added: 2026-03-16*
 
 Cloak raised only $1,455 against a $300,000 target (0.5% of target), entering refunding status. This represents a near-total failure of market validation, contrasting sharply with the 15x oversubscription pattern. The project had shipped product (live mainnet beta with Oro integration), had credible team (repeat builders, Superteam contributors), and addressed a real problem (MEV extraction on DCA orders). Despite these fundamentals, the futarchy-governed raise failed to attract capital, suggesting that product-market fit and team credibility are insufficient without pre-existing community or distribution.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
+
+Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment
 PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
 EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic
+
+
+## Key Facts
+- WHO issued conditional (not full) recommendations for GLP-1 medicines in obesity treatment in December 2025
+- WHO framework has three pillars: population-level policies, high-risk protection, and person-centered care
+- WHO guideline emphasizes GLP-1s must be combined with healthy diets, physical activity, and professional support
+- WHO requires countries to assess local cost-effectiveness and budget impact before adoption

inbox/archive/2026-03-05-futardio-launch-phonon-studio-ai.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/x1yqPH8mutuiqkrz66DPwFw1ykQqT4v5KyUUtUzBgPA"
 date: 2026-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["futarchy-governed-memecoin-launchpads-face-reputational-risk-tradeoff-between-adoption-and-credibility.md", "metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Launch Details
@@ -173,3 +177,13 @@ Phonon is already live which means there is real product market validation, meas
 - Token mint: `J697wnGGP8yWhYSrrMNsfH7cpKqp8up4uteigCHZmeta`
 - Version: v0.7
 - Closed: 2026-03-06
+
+
+## Key Facts
+- Phonon Studio AI launched on Futardio 2026-03-05 with $88,888 USDC target
+- Phonon Studio AI fundraise entered refunding status by 2026-03-06
+- Phonon generated 1000+ AI songs in first week of operation
+- Phonon uses Meteora Dynamic Bonding Pool protocol for artist token trading
+- Phonon proposed $11,777 monthly operational allowance
+- Phonon token: J69, mint address J697wnGGP8yWhYSrrMNsfH7cpKqp8up4uteigCHZmeta
+- Phonon launch address: x1yqPH8mutuiqkrz66DPwFw1ykQqT4v5KyUUtUzBgPA